India–Brazil Healthcare Dialogue Unlocks Growth: 17 Percent YoY Pharma Export Surge & New Market Opportunities

NEW DELHI, Feb 25: The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) supported the India–Brazil Healthcare Business Gateway held at Taj Palace, New Delhi, bringing together Indian pharmaceutical manufacturers, regulatory authorities, and Brazilian healthcare leaders. Organized by Amoveri Farma during the official visit of the Brazilian delegation, the closed-door meeting focused on expanding cooperation in oncology medicines, biosimilars, complex therapies, and hospital technologies, while facilitating structured access to the Brazilian market.

The meeting included participation from Amoveri Farma leadership, ANVISA representatives, and regulatory specialists, underscoring the strategic importance of India–Brazil cooperation in healthcare innovation and access. Discussions also addressed compliance with ANVISA requirements and pathways to accelerate responsible market entry.

India's pharmaceutical exports to Brazil have shown significant growth, with the country currently ranked as the second-largest destination for Indian pharma exports by share.

Overall Export Performance (Values in USD Million)

· FY 2024-25: Total exports reached $778.49 million, an 18.74% increase from $655.64 million in FY 2023-24.

· Apr-Jan FY26 (Current Period): Exports totalled $740.33 million, reflecting a 17.03% growth compared to the $632.59 million recorded during the same period in FY25.

· Market Share: Brazil accounts for approximately 2.88% of India's total country-wise pharmaceutical exports.

The majority of exports between Apr'25 – Jan'26 are driven by formulations and biologicals, which saw the highest growth during this period.

Category	Growth %	Share %
Drugs Formulations & Biologicals	35.96%	61.10%
Bulk Drugs & Drug Intermediates	15.26%	29.28%
Vaccines	-46.19%	5.96%
Surgicals	-1.40%	3.16%
Ayush & Herbals	-39.45%	0.50%

These figures underscore the strategic importance of Brazil, particularly for Indian MSME manufacturers specializing in complex therapies and specialty medicines

Pharmexcil Chairman Namit Joshi emphasised,

 “Brazil represents a significant opportunity for Indian MSME pharmaceutical manufacturers, particularly in specialty medicines, public healthcare supply, technology partnerships and regulatory collaboration. Indian companies possess the technological capability as well as the manufacturing scale required to expand high-quality medicines’ access for the Brazilian population. This meeting represents a strategic step toward deepening this pharmaceutical collaboration between India and Brazil. PHARMEXCIL remains committed to supporting initiatives that foster sustainable partnerships and facilitate responsible entry into the Brazilian market.”

Amoveri Farma, CEO, Guilherme Lima highlighted,

 “This meeting represents a significant step toward expanding pharmaceutical collaboration and improving access to advanced treatments in Brazil through partnerships with Indian manufacturers.”

As a nodal agency, Pharmexcil's commitment to global collaboration is evident through various engagements across countries. iPHEX 2026, scheduled for 7-9 September 2026 is also set to serve as a global platform to showcase India's pharmaceutical capabilities, fostering innovation and international partnerships. Pharmexcil continues to enhance buyer-seller communications and simplify essential processes through digital services, ensuring efficiency and increase the ease of doing business globally.